Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:21126942rdf:typepubmed:Citationlld:pubmed
pubmed-article:21126942lifeskim:mentionsumls-concept:C0024141lld:lifeskim
pubmed-article:21126942lifeskim:mentionsumls-concept:C0383327lld:lifeskim
pubmed-article:21126942lifeskim:mentionsumls-concept:C0229671lld:lifeskim
pubmed-article:21126942lifeskim:mentionsumls-concept:C1999216lld:lifeskim
pubmed-article:21126942lifeskim:mentionsumls-concept:C0243173lld:lifeskim
pubmed-article:21126942pubmed:issue4lld:pubmed
pubmed-article:21126942pubmed:dateCreated2010-12-17lld:pubmed
pubmed-article:21126942pubmed:abstractTextOverproduction of inflammation-related cytokines plays an important role in systemic lupus erythematosus (SLE). A crucial cytokine is IL-18, a member of the IL-1 family involved in the regulation of both innate and acquired immune responses. The aim of this study was to evaluate free IL-18 levels in the serum and urine of SLE patients, in order to establish their relationship with other biomarkers of disease activity. Serum and urine levels of IL-18 and IL-18BP were measured by ELISA in 50 SLE patients and in 32 healthy subjects; free IL-18 was calculated using the law of mass action. Serum levels of total IL-18, IL-18BP and free IL-18 were higher in SLE patients than in healthy controls. Total and free serum IL-18 levels were higher in patients with active disease (with nephritis or active non-renal disease), and correlated with the ECLAM score. Urinary levels of total and free IL-18 were higher in patients than in controls, but did not correlate with disease activity. The data collected in this study show that increased levels of both IL-18 and its natural inhibitor IL-18BP, characterise SLE. Despite the overproduction of IL-18BP, free IL-18 is still significantly higher in SLE patients than in controls, and its serum levels are a marker of disease activity.lld:pubmed
pubmed-article:21126942pubmed:languageenglld:pubmed
pubmed-article:21126942pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21126942pubmed:citationSubsetIMlld:pubmed
pubmed-article:21126942pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21126942pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21126942pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21126942pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21126942pubmed:statusMEDLINElld:pubmed
pubmed-article:21126942pubmed:monthDeclld:pubmed
pubmed-article:21126942pubmed:issn1148-5493lld:pubmed
pubmed-article:21126942pubmed:authorpubmed-author:DinarelloChar...lld:pubmed
pubmed-article:21126942pubmed:authorpubmed-author:PratesiFederi...lld:pubmed
pubmed-article:21126942pubmed:authorpubmed-author:MiglioriniPao...lld:pubmed
pubmed-article:21126942pubmed:authorpubmed-author:BoraschiDiana...lld:pubmed
pubmed-article:21126942pubmed:authorpubmed-author:QuattroniPaol...lld:pubmed
pubmed-article:21126942pubmed:authorpubmed-author:AnzilottiCons...lld:pubmed
pubmed-article:21126942pubmed:authorpubmed-author:BargagnaMarco...lld:pubmed
pubmed-article:21126942pubmed:issnTypePrintlld:pubmed
pubmed-article:21126942pubmed:day1lld:pubmed
pubmed-article:21126942pubmed:volume21lld:pubmed
pubmed-article:21126942pubmed:ownerNLMlld:pubmed
pubmed-article:21126942pubmed:authorsCompleteYlld:pubmed
pubmed-article:21126942pubmed:pagination264-71lld:pubmed
pubmed-article:21126942pubmed:meshHeadingpubmed-meshheading:21126942...lld:pubmed
pubmed-article:21126942pubmed:meshHeadingpubmed-meshheading:21126942...lld:pubmed
pubmed-article:21126942pubmed:meshHeadingpubmed-meshheading:21126942...lld:pubmed
pubmed-article:21126942pubmed:meshHeadingpubmed-meshheading:21126942...lld:pubmed
pubmed-article:21126942pubmed:meshHeadingpubmed-meshheading:21126942...lld:pubmed
pubmed-article:21126942pubmed:meshHeadingpubmed-meshheading:21126942...lld:pubmed
pubmed-article:21126942pubmed:meshHeadingpubmed-meshheading:21126942...lld:pubmed
pubmed-article:21126942pubmed:meshHeadingpubmed-meshheading:21126942...lld:pubmed
pubmed-article:21126942pubmed:meshHeadingpubmed-meshheading:21126942...lld:pubmed
pubmed-article:21126942pubmed:meshHeadingpubmed-meshheading:21126942...lld:pubmed
pubmed-article:21126942pubmed:meshHeadingpubmed-meshheading:21126942...lld:pubmed
pubmed-article:21126942pubmed:meshHeadingpubmed-meshheading:21126942...lld:pubmed
pubmed-article:21126942pubmed:meshHeadingpubmed-meshheading:21126942...lld:pubmed
pubmed-article:21126942pubmed:meshHeadingpubmed-meshheading:21126942...lld:pubmed
pubmed-article:21126942pubmed:meshHeadingpubmed-meshheading:21126942...lld:pubmed
pubmed-article:21126942pubmed:year2010lld:pubmed
pubmed-article:21126942pubmed:articleTitleSerum and urinary levels of IL-18 and its inhibitor IL-18BP in systemic lupus erythematosus.lld:pubmed
pubmed-article:21126942pubmed:affiliationClinical Immunology Unit, Department of Internal Medicine, University of Pisa, Via Roma 67, Pisa, Italy. p.migliorini@med.unipi.itlld:pubmed
pubmed-article:21126942pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:21126942pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
entrez-gene:3606entrezgene:pubmedpubmed-article:21126942lld:entrezgene
entrez-gene:10068entrezgene:pubmedpubmed-article:21126942lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:21126942lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:21126942lld:entrezgene